| |
Baseline (90 min)
|
After 60 min hypertonic saline infusion (150 min)
|
90 min post hypertonic saline infusion (210 min)
|
P-value (difference in response)
|
|---|
|
p-AVP (ng/L)
|
|
Placebo
|
0.20 (0.20;0.20)
|
0.50(0.40;0.70)*
|
0.20(0.20;0.23)
|
< 0.001
|
|
Furosemide
|
0.20 (0.18;0.20)
|
0.90(0.60;1.10)*,†
|
0.30(0.20;0.40)*,†
|
|
PRC (ng/L)
|
|
Placebo
|
9.0 (5.3;13.0)
|
7.3 (4.4;10.9)*
|
5.6 (2.9;7.4)*
|
0.001
|
|
Furosemide
|
10.3 (5.8;16.9)
|
9.3 (7.7;16.2)†
|
8.0 (5.3;19.3)†
|
|
p-AngII (ng/L)
|
|
Placebo
|
12 (8;18)
|
7 (5;13)*
|
6 (4;11) *
|
0.014
|
|
Furosemide
|
16 (9;22)
|
16 (11;20)†
|
16 (9;24)†
|
|
p-Aldo (pmol/L)
|
|
Placebo
|
240 (200;342)
|
167 (144;211)*
|
169 (161;213)*
|
0.001
|
|
Furosemide
|
277 (232;377)
|
256 (228;328)†
|
262 (201;325)†
|
- p-AVP Plasma concentrations arginine vasopressin, PRC renin, p-AngII angiotensin II and p-Aldo aldosterone were measured before hypertonic saline infusion, after 60 min of saline infusion, and 90 min after cessation of saline infusion on the examination day. Data are shown as medians with 25 and 75 percentiles in brackets. P-value represents probability of difference in response to saline (response from baseline to saline infusion) between treatments. Students t-test was used to test difference in response to saline between treatments. Wilcoxon signed rank test was used to test statistical significant difference from baseline, * = p < 0.05, and from Placebo, † = p < 0.05
